Korro amended its research collaboration and license agreement with Novo Nordisk A/S (Novo Nordisk). This amendment establishes a 12-month pause to reassess the rationale for the current target under ...
Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS), today announced that the first ...
Muscular Dystrophy Association Names Sharon Hesterlee, PhD, as President and Chief Executive Officer
New York, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the appointment of Sharon Hesterlee, PhD as President and Chief Executive Officer. Dr. Hesterlee ...
Absci accelerates ABS-201 in alopecia & endometriosis, targets data by 2027, and refocuses pipeline for value.
PublicSource on MSN
Cuts in funds for HIV services threaten medication access, outreach
The Pennsylvania Department of Health will cut 25% of funding to the Part B of the Ryan White HIV/AIDS Program amid rising need and tighter eligibility rules.
Appointed key leadership to drive (Z)-endoxifen development and evolve pathway to commercialization SEATTLE, /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a ...
Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With ...
What, according to you, are the most critical forces shaping the future of healthcare in India, and how do you see the sector ...
AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune diseases, today announced the publication of new ...
CITIZ3N Government Solutions, a technology provider for government agencies overseeing health benefits, announced updates to its VERIFY platform to align with new Medicaid eligibility requirements in ...
It was a number quietly dropped into a speech by a senior army officer in the southern NSW city of Wagga Wagga.
Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results